Who we are.
Third-largest global player in the €190 billion OTC & VMS market, delivering compelling growth through 100 beloved brands serving 500 million consumers worldwide1. Backed by CD&R and driven by our mission — “Health. In your hands” — we are unlocking long-term value creation, empowering consumers to take charge of their health.
Press Release.
Opella reprices its two term loan B facilities.
Financial calendar.
Next financial communication: 2026 H1 results will be published end of September 2026.
As of April 2025, Opella is proud to be the first global consumer healthcare company to achieve B CorpTM Certification, meeting the rigorous social, environmental, and governance standards set by B Lab.
Contact us.
For any inquiries, please contact our Investor Relations team at investors@opella.com.
- Internal Opella penetration study 2023.
- According to Nicholas Hall's DB6 2024™.
- Opella data, FY 2024 published financial results.
